Literature DB >> 496551

Thought, language, and communication disorders. I. Clinical assessment, definition of terms, and evaluation of their reliability.

N C Andreasen.   

Abstract

Bleulerian psychiatry has considered thought disorder to be a pathognomonic symptom of schizophrenia. Evaluation of the Bleulerian perspective has been severely handicapped by the lack of any standard and widely agreed-on definition of thought disorder. Consequently, the conceptualization of thought disorder has tended to be quite diverse, and evaluation of thought disorder has tended to be quite unreliable. This report presents a set of definitions of linguistic and cognitive behaviors frequently observed in patients. These definitions derive from clinical experience, use an empirical approach, and avoid making inferences about underlying processes of thought. They attempt to define the broad range of language, thought, and communication behaviors observed in patients and are not limited to those considered characteristic of schizophrenia. The reliability of these definitions has been assessed using both tape-recorded and live interviews with patients, and it has been found to be quite good for most of the terms defined.

Entities:  

Mesh:

Year:  1979        PMID: 496551     DOI: 10.1001/archpsyc.1979.01780120045006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  77 in total

1.  Altered language network activity in young people at familial high-risk for schizophrenia.

Authors:  H W Thermenos; S Whitfield-Gabrieli; L J Seidman; G Kuperberg; R J Juelich; S Divatia; C Riley; G A Jabbar; M E Shenton; M Kubicki; T Manschreck; M S Keshavan; L E DeLisi
Journal:  Schizophr Res       Date:  2013-10-28       Impact factor: 4.939

2.  Spared bottom-up but impaired top-down interactive effects during naturalistic language processing in schizophrenia: evidence from the visual-world paradigm.

Authors:  Hugh Rabagliati; Nathaniel Delaney-Busch; Jesse Snedeker; Gina Kuperberg
Journal:  Psychol Med       Date:  2018-08-22       Impact factor: 7.723

Review 3.  Language as a biomarker for psychosis: A natural language processing approach.

Authors:  Cheryl M Corcoran; Vijay A Mittal; Carrie E Bearden; Raquel E Gur; Kasia Hitczenko; Zarina Bilgrami; Aleksandar Savic; Guillermo A Cecchi; Phillip Wolff
Journal:  Schizophr Res       Date:  2020-06-01       Impact factor: 4.939

4.  Cognitive control components and speech symptoms in people with schizophrenia.

Authors:  Theresa M Becker; David C Cicero; Nelson Cowan; John G Kerns
Journal:  Psychiatry Res       Date:  2012-02-22       Impact factor: 3.222

5.  On identifying the processes underlying schizophrenic speech disorder.

Authors:  Nancy M Docherty
Journal:  Schizophr Bull       Date:  2011-05-11       Impact factor: 9.306

6.  Thought disorder and communication deviance as predictors of outcome in youth at clinical high risk for psychosis.

Authors:  Carrie E Bearden; Keng Nei Wu; Rochelle Caplan; Tyrone D Cannon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-06-02       Impact factor: 8.829

7.  Formal thought disorder in autism spectrum disorder predicts future symptom severity, but not psychosis prodrome.

Authors:  Mart L J M Eussen; Esther I de Bruin; Arthur R Van Gool; Anneke Louwerse; Jan van der Ende; Fop Verheij; Frank C Verhulst; Kirstin Greaves-Lord
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-05-10       Impact factor: 4.785

8.  Disordered discourse in schizophrenia described by the Structure Building Framework.

Authors:  Morton Ann Gernsbacher; Kathleen A Tallent; Caroline M Bolliger
Journal:  Discourse Stud       Date:  1999-08

9.  Though disorder in high-functioning autistic adults.

Authors:  E Dykens; F Volkmar; M Glick
Journal:  J Autism Dev Disord       Date:  1991-09

10.  Abnormal cortical folding patterns within Broca's area in schizophrenia: evidence from structural MRI.

Authors:  Jonathan J Wisco; Gina Kuperberg; Dara Manoach; Brian T Quinn; Evelina Busa; Bruce Fischl; Stephan Heckers; A Gregory Sorensen
Journal:  Schizophr Res       Date:  2007-05-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.